Lupus Nefritini n Tedavisi

1. Mok CC, Tang SSK. Incidence and predictors of renal disease in Chinese patients with systemic lupus erythematosus. Am J Med 2004;117:791-5.
2. Appel GB, Valeri A. The course and treatment of lupus neph¬ritis. Annu Rev Med 1994;45:525-37.
3. Austin III HA, Klippel JH, Balow JE, et al. Therapy of lupus nephritis: Controlled trial of prednisone and cytotoxic drugs. N Eng J Med 1986; 314:614-9.
4. Mok CC, Ying KY, Tang S, et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rhe¬um 2004;50:2559-68.
5. Mok CC, Ho CTK, Siu YP, et al. Treatment of diffuse prolife-
rative lupus glomerulonephritis: A comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis 2001;38:256-64.
6. Sesso R, Monteiro M, Sato E, Kirsztajn G, Silva L, Ajzen H. A controlled trial of pulse cyclophosphamide versus pulse methyl-prednisolone in severe lupus nephritis. Lupus 1994;
3:107-12.
7. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosupp-ressive therapy in lupus nephritis. The Euro-lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intra¬venous cyclophosphamide. Arthritis Rheum 2002;46:2121-31.
8. Takada K, Illei GG, Boumpas DT. Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus 2001;10:
154-61.
9. Boumpas DT, Austin III HA, Vaughan EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-5.
10. Illei GG, Takada K, Parkin D, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy. Long term follow-up of a cohort of 145 patients participating in randomized cont¬rolled studies. Arthritis Rheum 2002;46:995-1002.
11. Illei GG, Austin III HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolo-ne improves long term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001;135:
248-57.
12. Huong Du L, Amoura Z, Duhaut P, et al. Risk of ovarian fa¬ilure and fertility after intravenous cyclophosphamide. A
study in 84 patients. J Rheumatol 2002;29:2571-6.
13. Mok CC, Ho CK, Chan KW, Lau CS, Wong RW. Outcome and prognostic indicators of diffuse proliferative lupus glomeru-lonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum 2002;46:1003-13.
14. Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 1998;41:831-7.
15. Rivkees SA, Crawford JD. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA
1988;259: 2123-5.
16. Fulton B, Markham A. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clini¬cal efficacy in renal transplantation. Drugs 1996;51:278-98.
17. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group.
Transplantation 1995;60:225-32.
18. Briggs WA, Choi MJ, Scheel PJ Jr. Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis
1998; 31:213-17.
19. Hu W, Liu Z, Chen H, et al. Mycophenolate mofetil vs cyclop-hosphamide therapy for patients with diffuse proliferative lu¬pus nephritis. Chin Med J 2002;115:705-9.
20. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Eng J Med 2004;350:971-
80.
21. Chan TM. Preventing renal failure in patients with severe lu¬pus nephritis. Kidney International Suppl 2005;67:116-9.
22. Braun N, Erley C, Klein R, Kotter I, Saal J, Risler T. Immuno-adsorption onto protein A induces remission in severe syste-
Official Journal of the Turkish Society of Nephrology / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi
75
0 Treatment of Lupus Nephritis
mic lupus erythematosus. Nephrol Dial Transplant 2000;15:
1367-72.
23. Pfueller B, Wolbart K, Bruns A, Burmester GR, Hiepe F. Suc¬cessful treatment of patients with systemic lupus erythemato-sus by immunoadsorption with a C1q column: A pilot study.
Arthritis Rheum 2001;44:1962-3.
24. Levy Y, Sherer Y, George J, et al. Intravenous immunoglobu-lin treatment of lupus nephritis. Semin Arthritis Rheum 2000;
29:321-7.
25. Furie RA, Cash JM, Cronin ME, et al. Treatment of systemic
lupus erythematosus with LJP 394. J Rheumatol 2001;28:257-
65.
26. Alarcon-Segovia D, Tumlin JA, Furie RA, et al. LJP 394 for the prevention of renal flare in patients with systemic lupus eryt-hematosus: Results from a randomized, double-blind, place¬bo-controlled study. Arthritis Rheum 2003;48: 442-54.
27. Chan TM, Li FK, Hao WK, et al. Treatment of membranous lupus nephritis with nephrotic syndrome by sequential im-munosuppression. Lupus 1999;8:545-51.
28. Austin HA, Vaughan EM, Balow JE. Lupus membranous nephropathy: Randomized controlled trial of prednisone, cyclosporine and cyclophosphamide. J Am Soc Nephrol
2000;11:A81.
29. Borber EF, Guedes LK, Figuiredo CP, Christmann RB, Gon-calves CR, Bonfa E. Prospective study of MMF in lupus membranous nephritis. Arthritis Rheum 2004;50:S448.
30. Lai KL, Tang SCW, Mok CC. Treatment for lupus nephritis : A revisit. Nephrology 2005;10:180-8.
31. Ward MM, Pyun E, Studenski S. Causes of death in systemic lupus erythematosus. Long-term follow-up of an inception
cohort. Arthritis Rheum 1995;38:1492-9.
32. Clark WF, Moist LM. Management of chronic renal insuffici¬ency in lupus nephritis: Role of proteinuria, hypertension and dyslipidemia in the progression of renal disease. Lupus
1998;7: 649-53.
33. Asanuma Y, Oeser A, Shintani AK, et al. Premature coronary artery atherosclerosis in systemic lupus erythematosus. N Eng J Med 2003;349:2407-15.